| Dr Justin Parschauer, DO | |
|
6600 S Yale Ave, Suite 800, Tulsa, OK 74136-3347 | |
| (918) 491-3900 | |
| Not Available |
| Full Name | Dr Justin Parschauer |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 18 Years |
| Location | 6600 S Yale Ave, Tulsa, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073845921 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | N5933 (Texas) | Secondary |
| 207W00000X | Ophthalmology | 4545 (Oklahoma) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tulsa Retina Consultants Pllc | 1850518861 | 3 |
News Archive
Low physical activity increases kidney transplant patients' likelihood of dying early, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology. The results suggest that patients need to exercise to fend off an early death.
Researchers at the University of California, San Diego School of Medicine have identified a protein critical to hematopoietic stem cell function and blood formation. The finding has potential as a new target for treating leukemia because cancer stem cells rely upon the same protein to regulate and sustain their growth.
In mammals, including humans, the heart muscle has a very limited capacity to recover after injury. After an acute myocardial infarction, millions of cardiac muscle cells, named cardiomyocytes, die, and are replaced by a scar.
Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each patient's tumor has also given researchers clearer understanding of which patients should receive the combination.
› Verified 7 days ago
| Entity Name | Tulsa Retina Consultants Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205263126 PECOS PAC ID: 1850518861 Enrollment ID: O20140815000773 |
News Archive
Low physical activity increases kidney transplant patients' likelihood of dying early, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology. The results suggest that patients need to exercise to fend off an early death.
Researchers at the University of California, San Diego School of Medicine have identified a protein critical to hematopoietic stem cell function and blood formation. The finding has potential as a new target for treating leukemia because cancer stem cells rely upon the same protein to regulate and sustain their growth.
In mammals, including humans, the heart muscle has a very limited capacity to recover after injury. After an acute myocardial infarction, millions of cardiac muscle cells, named cardiomyocytes, die, and are replaced by a scar.
Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each patient's tumor has also given researchers clearer understanding of which patients should receive the combination.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Justin Parschauer, DO 2424 E 21st St, Ste 200, Tulsa, OK 74114-1736 Ph: (918) 488-6001 | Dr Justin Parschauer, DO 6600 S Yale Ave, Suite 800, Tulsa, OK 74136-3347 Ph: (918) 491-3900 |
News Archive
Low physical activity increases kidney transplant patients' likelihood of dying early, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology. The results suggest that patients need to exercise to fend off an early death.
Researchers at the University of California, San Diego School of Medicine have identified a protein critical to hematopoietic stem cell function and blood formation. The finding has potential as a new target for treating leukemia because cancer stem cells rely upon the same protein to regulate and sustain their growth.
In mammals, including humans, the heart muscle has a very limited capacity to recover after injury. After an acute myocardial infarction, millions of cardiac muscle cells, named cardiomyocytes, die, and are replaced by a scar.
Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each patient's tumor has also given researchers clearer understanding of which patients should receive the combination.
› Verified 7 days ago
Mark Justin Weiss, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1717 S Utica Ave, Ste 107, Tulsa, OK 74104 Phone: 918-742-2428 Fax: 918-742-8435 | |
Anthony Economou, D.O. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2865 E Skelly Dr Ste 250, Tulsa, OK 74105 Phone: 918-317-0022 Fax: 855-327-9828 | |
Dr. Zeb Linston Brister, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 3906 S Peoria Ave, Tulsa, OK 74105 Phone: 918-585-1523 Fax: 918-584-5520 | |
John Thomas Romano, D.O. Ophthalmology Medicare: Medicare Enrolled Practice Location: 4444 S Harvard Ave, Ste 300, Tulsa, OK 74135 Phone: 918-747-2020 Fax: 918-747-2056 | |
Dr. Bruce Ben Pettigrove, M.D. Ophthalmology Medicare: May Accept Medicare Assignments Practice Location: 6606 S. Yale, #220, Tulsa, OK 74136 Phone: 918-492-4122 Fax: 918-492-7451 | |
Shehzad Y Batliwala, D.O Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 10010 E 81st St Ste 100, Tulsa, OK 74133 Phone: 918-250-2020 |